Monte Rosa Therapeutics develops small molecule drugs that break down proteins tied to immune disorders and cancers. It last closed at $9.07 on Nov 17, down 0.98% on the day. The average 12-month price target from 5 analysts is $24.80 (+173.4% from the last close), with a high of $28.00 and a low of $19.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).
Each firm's latest rating on GLUE in the past 90 days
Average 12-month target
$24.80
▲ 173.4% upside
Based on 5 analysts who set a price target on GLUE in the past 90 days. The average target is $24.80, with a high of $28.00 and a low of $19.00, compared with the last close of $9.07.
Low $19.00Avg $24.80High $28.00
Blue marker: last close $9.07
Highest target$28.00
Average target$24.80
Lowest target$19.00
Latest rating changes
Wells FargoTarget lowered
Nov 6Buy$27 → $25
UBSAssumed coverage
Oct 12Buy$19
HC Wainwright & Co.Reiterated
Oct 5Buy$25
HC Wainwright & Co.Initiated
Oct 1Buy$25
WedbushReiterated
Sep 9Buy$27
Date
Firm
Action
Rating
Price target
Nov 6
Wells Fargo
Target lowered
Buy
$27 → $25
Oct 12
UBS
Assumed coverage
Buy
$19
Oct 5
HC Wainwright & Co.
Reiterated
Buy
$25
Oct 1
HC Wainwright & Co.
Initiated
Buy
$25
Sep 9
Wedbush
Reiterated
Buy
$27
Loading…
Technical Analysis
GLUE · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 15% below its 20 day and 22% below its 50 day average. It is 83% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the Pivot at $9.06, and the nearest resistance the Pivot R1 at $9.29.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.7%/day
Key levels
$25.7752 week high+184.1%
$16.63200 day average+83.4%
$14.98100 day average+65.2%
$11.1050 day average+22.4%
$10.85Swing high (Nov 10)+19.6%
$10.3920 day average+14.6%
$9.29Pivot R1+2.4%
$9.07Last close
$9.06Pivot−0.1%
$8.84Pivot S1−2.5%
$8.8352 week low−2.6%
Indicators
RSI (14)
30.92
Weak, oversold below 30
Neutral
MACD
-0.51
Below its signal line
Bearish
Stochastic
12.8
Near the bottom of its range
Oversold
ADX (14)
27.3
Trending down
Williams %R
-89.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-192.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−12.9%
Change over 10 sessions
Bearish
ATR (14)
$0.61
Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityNormal, 21.5%/day
Key levels
$25.7752 week high+184.1%
$16.63200 day average+83.4%
$14.98100 day average+65.2%
$11.1050 day average+22.4%
$10.85Swing high (Nov 10)+19.6%
$10.3920 day average+14.6%
$9.29Pivot R1+2.4%
$9.07Last close
$9.06Pivot−0.1%
$8.84Pivot S1−2.5%
$8.8352 week low−2.6%
Indicators
RSI (14)
32.42
Weak, oversold below 30
Neutral
MACD
-2.21
Below its signal line
Bearish
Stochastic
7.0
Near the bottom of its range
Oversold
ADX (14)
30.4
Trending down
Williams %R
-96.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-94.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−35.5%
Change over 10 sessions
Bearish
ATR (14)
$1.95
Typical daily range, 21.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for GLUE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how GLUE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow GLUE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GLUE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GLUE is in one of them and how their past GLUE trades turned out.
Monte Rosa Therapeutics is a biotechnology company based in Boston, Massachusetts. It develops small molecule drugs called molecular glue degraders, which use the body's natural protein disposal system to break down proteins tied to disease. Its candidates are in clinical trials for immune conditions, inflammatory diseases, and prostate cancer, and it is developing programs for other cancers. Its main partner is Novartis, which has licensed one of its immune disease programs.